Tylenol — Autism & ADHD Claims
The 2026 Appeals Ruling — What It Means for Your Family
The appeals court revived the cases and sent them back to the federal trial court. What you can know today, in two minutes, is whether your family qualifies.
ACTIVE — NO SETTLEMENT. ~550 cases revived July 13, 2026 · returned to the federal trial court · new claims still reviewed.
Did you take Tylenol — or store-brand acetaminophen — while pregnant?
Yes — Check My Family’s Claimtakes 2 minutes I think so / not sureFree · confidential · no documents needed · answering doesn’t commit you to anything
Prefer to talk it through? (888) 348-2735 — free and confidential.
Stefanie A. Murphy & Matthew T. Marin
Partners
You’ll get a straight answer even if it’s “you don’t qualify.” Everything you share is confidential — even if you never hire us. No fee unless there is a recovery; costs are advanced and reimbursed only out of a recovery. No records are needed for the free review.
No court has found that Tylenol causes autism or ADHD, and no settlement has been reached.
Litigation status — updated November 7, 2026: On July 13, 2026, the U.S. Court of Appeals for the Second Circuit set aside the judgments that had dismissed roughly 550 acetaminophen (Tylenol) autism/ADHD cases. It held that the testimony of three of the plaintiffs’ general-causation experts is admissible, and it rejected the defendants’ argument that federal law blocks these claims. On October 16, 2026, the court denied rehearing in the main appeal. On October 28, 2026, its mandate was docketed in the federal trial court in New York, returning those cases there; no schedule has been set yet. The October 16 order denying rehearing also lists the related Phippen appeal, which involves one ADHD expert. Any Supreme Court petition in the main appeal is due January 14, 2027, and that deadline can be extended; as of November 7, 2026, none appears on the Supreme Court’s docket. The appeals court expressly did not decide whether acetaminophen causes autism or ADHD, and it did not decide whether any case will succeed. There is no trial date and no settlement. (Rutledge v. Walgreen Co., Nos. 24-916, 24-1121, 24-2360; Phippen v. Walgreen Co., No. 24-2594 (2d Cir.); unsealed opinion released July 17, 2026.)
As of November 7, 2026: the public RECAP archive indexes at least 78 cases filed this year in the Southern District of New York against Johnson & Johnson Consumer whose dockets mention acetaminophen, 35 of them since September 30. See the member-case ledger.
If you took Tylenol during pregnancy and your child was later diagnosed with autism or ADHD, a free review can tell you whether your family fits the firm’s current screening criteria. Get a free case review or call (888) 348-2735.
Free, confidential case review. No fee unless there is a recovery. The firm advances court costs and litigation expenses, and those expenses are repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted. Start your free case review or call (888) 348-2735.
Key Takeaways
- What happened: On July 13, 2026, the U.S. Court of Appeals for the Second Circuit set aside the judgments that had ended the federal Tylenol autism and ADHD cases and sent them back to the trial court. On October 16, 2026, it denied rehearing in the main appeal, so the July decision stands.
- The experts: The court held that the trial court should not have excluded three of the plaintiffs’ experts. It sent the ADHD expert’s exclusion in Phippen back for reconsideration.
- What the court did not decide: whether Tylenol or acetaminophen causes autism or ADHD. No court has decided that question.
- No settlement: as of November 7, 2026, we have found no settlement, and no court has found that Tylenol causes autism or ADHD.
- What comes next: the Second Circuit’s mandate, returning the cases to the trial court, was docketed there on October 28, 2026. Any Supreme Court petition in the main appeal is due January 14, 2027, and that deadline can be extended. The October 16, 2026 order denying rehearing also lists the Phippen appeal.
- For parents: If you took acetaminophen while pregnant and your child was later diagnosed with autism or ADHD, a free review can tell you whether your family’s situation fits the firm’s current screening criteria. Filing deadlines apply, and the free review doesn’t calculate or track yours.
Related Tylenol lawsuit coverage: Tylenol autism lawsuit — full 2026 guide | when will the Tylenol autism lawsuit be settled? | Tylenol settlement amounts: why none exist yet | Tylenol autism lawsuit sign-up · The Boston Birth Cohort cord-blood study · How Tylenol claims are evaluated · MDL 3043 docket tracker · Do I qualify? The criteria explained · The Rule 702 holdings, explained for lawyers
What the Second Circuit Decided on July 13, 2026
The decision came in two cases heard together: Rutledge v. Walgreen Co. (No. 24-916) and Phippen v. Walgreen Co. (No. 24-2594). A three-judge panel — Judges Calabresi, Lynch, and Lee — issued the ruling, with the opinion written by Judge Guido Calabresi.
In plain English, the appeals court vacated and remanded: it set aside the trial court’s judgments for the defendants and sent the cases back for more proceedings. The opinion says the trial court had granted summary judgment in about 550 cases.
The lawsuits sit inside a large federal case called a multidistrict litigation, or MDL, in the Southern District of New York (In re Acetaminophen — ASD-ADHD Products Liability Litigation, No. 22-md-3043, before Judge Denise Cote). An MDL gathers many similar cases before one judge to handle shared questions efficiently. You can read the ruling yourself in the Second Circuit opinion (PDF) and follow the case on the trial court’s MDL 3043 page.
The Three Experts the Court Said Should Not Have Been Excluded
The heart of the ruling is about expert witnesses. In science-based injury cases, each side relies on experts to explain what the research shows. The trial court had excluded the plaintiffs’ general-causation experts, and that ruling led to the judgments for the defendants.
The Second Circuit held that the trial court “exceeded its discretion” in excluding three of those experts:
- Dr. Andrea Baccarelli, an epidemiologist
- Dr. Eric Hollander, a psychiatrist
- Dr. Brandon Pearson, a toxicologist
Be clear about what this means. Letting these experts back in is not a finding that Tylenol causes autism or ADHD. The appeals court held that excluding them was wrong, and the trial court will apply that ruling now that the cases are back before it.
The Phippen Appeal
For a third expert in the Phippen case, Dr. Roberta Ness, the court vacated the exclusion so the trial court can reconsider it. The appeals court expressed no opinion on whether her testimony should ultimately be allowed. That question is left to the trial court.
Why Federal Law Did Not Block the Claims (Preemption)
The manufacturers also argued that federal law should stop these lawsuits — a defense called “preemption.” The idea was that because the FDA sets the pregnancy warning for these products, a company could not be blamed under state law for failing to warn.
The Second Circuit rejected that argument. It explained that the FDA’s Pregnancy Warning Regulation (21 C.F.R. § 201.63) requires a general warning but does not forbid a manufacturer from adding a stronger, supplemental warning. Because a company could have added more warning on its own, the failure-to-warn claims may go forward. Quoting the Supreme Court’s decision in Wyeth v. Levine, the court noted that “impossibility pre-emption is a demanding defense.”
Key Quote From the Opinion
The court went out of its way to spell out the limits of its decision. In its own words:
“We are not deciding whether there is a general causal relationship between acetaminophen and ADHD and/or ASD. We are also not deciding whether the manufacturers of acetaminophen must warn consumers.”
So while the ruling sends the cases back, it does not establish that Tylenol causes autism or ADHD. No liability has been found, and the science remains subject to ongoing debate. Some scientific studies have reported associations between acetaminophen use in pregnancy and autism or ADHD, but that question is still debated, and the FDA has not concluded that acetaminophen causes either condition. You can find general information from the regulator on the FDA website.
Free, confidential case review. No fee unless there is a recovery. Start your free case review or call (888) 348-2735.
What Happens Next on Remand
“Remand” means the cases return to the district court in New York for further proceedings. There, applying the appeals court’s ruling on the experts, the litigation can move forward through the usual pretrial steps. On October 28, 2026, the Second Circuit’s mandate was docketed in the federal trial court in New York, returning the cases there. As of November 7, 2026, no petition for review has been filed in the main appeal. Any petition is due January 14, 2027, and that deadline can be extended. The appeals court’s opinion noted studies published since the 2023 ruling and said the trial court may invite the parties to address them. The trial court will manage next stages of the MDL, and both sides will continue to build their cases.
No one can promise how long this will take or how it will end. There is no settlement and no verdict. For a realistic look at timing, see our companion page on when the Tylenol autism lawsuit may be settled. as of November 7, 2026, we have found no settlement, and no one can say whether there will be one, or when.
Tylenol Lawsuit Docket Timeline, With Sources
- October 16, 2026: the Second Circuit denies rehearing in the main appeal (Nos. 24-916, 24-1121 and 24-2360). The Phippen appeal (No. 24-2594) is also listed in the same order.
- September 10, 2026: rehearing petitions are filed in the main appeal and in Phippen.
- July 17, 2026: a copy of the opinion is filed on the trial court’s docket.
- July 13, 2026: the Second Circuit vacates the judgments and remands (its opinion counts about 550 cases decided on summary judgment), holding that three of the plaintiffs’ experts should not have been excluded and upholding the exclusion of two others.
- December 2023: the trial court excludes the plaintiffs’ experts; judgments for the defendants follow in 2024.
- October 2022: the federal cases are centralized as MDL 3043 in the Southern District of New York.
Sources: Second Circuit opinion (PDF) · MDL 3043 docket · Phippen appeal docket (No. 24-2594) · the S.D.N.Y. court’s MDL 3043 page. Litigation status and court records checked November 7, 2026.
Member-case ledger: Tylenol autism/ADHD lawsuits filed in 2026
As of November 7, 2026: the Second Circuit decided the appeal in the Tylenol autism/ADHD litigation (Rutledge v. Walgreen Co., Nos. 24-916, 24-2594) on July 13, 2026, denied rehearing in the main appeal on October 16, 2026, and its mandate in the main appeal was docketed in the trial court on October 28, 2026. The public RECAP archive indexes at least 78 cases filed against Johnson & Johnson Consumer in the Southern District of New York in 2026 whose dockets mention acetaminophen, 59 of them since June 1 and 35 since September 30.
New indexed cases by month of filing, 2026 — 01/2026: 3 · 02/2026: 6 · 03/2026: 3 · 04/2026: 2 · 05/2026: 5 · 06/2026: 5 · 07/2026: 4 · 08/2026: 7 · 09/2026: 9 · 10/2026 (through Oct. 14): 4.
| Case | Filed | S.D.N.Y. docket |
|---|---|---|
| Czubiak v. Johnson & Johnson Consumer, Inc. | 10/05/2026 | 1:26-cv-08776 |
| Morris v. Johnson & Johnson Consumer, Inc. | 10/01/2026 | 1:26-cv-08678 |
| Collado v. Johnson & Johnson Consumer, Inc. | 10/01/2026 | 1:26-cv-08666 |
| Quero v. Johnson & Johnson Consumer, Inc. | 10/01/2026 | 1:26-cv-08658 |
| McKay v. Johnson & Johnson Consumer Inc. | 09/30/2026 | 1:26-cv-08590 |
| White v. Johnson & Johnson Consumer Inc. | 09/25/2026 | 1:26-cv-08368 |
| McArdle v. Johnson & Johnson Consumer Inc. | 09/22/2026 | 1:26-cv-08231 |
| Ramos v. Johnson & Johnson Consumer Inc. | 09/17/2026 | 1:26-cv-08112 |
| Walker v. Johnson & Johnson Consumer Inc. | 09/11/2026 | 1:26-cv-07920 |
| Barro v. Johnson & Johnson Consumer, Inc. | 09/10/2026 | 1:26-cv-07908 |
| Bingham v. Johnson & Johnson Consumer Inc. | 09/03/2026 | 1:26-cv-07542 |
| Dela Piniella v. Johnson & Johnson Consumer, Inc. | 09/02/2026 | 1:26-cv-07527 |
| Estrada v. Johnson & Johnson Consumer, Inc. | 09/02/2026 | 1:26-cv-07521 |
| Brogren v. Johnson & Johnson Consumer, Inc. | 08/31/2026 | 1:26-cv-07424 |
| Devlin v. Johnson & Johnson Consumer Inc. | 08/27/2026 | 1:26-cv-07319 |
| Bethea v. Johnson & Johnson Consumer Inc. | 08/27/2026 | 1:26-cv-07316 |
| Rodriguez-Santana v. Johnson & Johnson Consumer, Inc. | 08/21/2026 | 1:26-cv-07137 |
| Beaity v. Johnson & Johnson Consumer Inc | 08/18/2026 | 1:26-cv-07043 |
| J. v. Johnson & Johnson Consumer Inc | 08/14/2026 | 1:26-cv-06959 |
| Lambert v. Johnson & Johnson Consumer, Inc. | 08/06/2026 | 1:26-cv-06716 |
| Wessel v. Johnson & Johnson Consumer, Inc. | 07/31/2026 | 1:26-cv-06570 |
| Noseworthy v. Johnson & Johnson Consumer, Inc. | 07/30/2026 | 1:26-cv-06527 |
| Wittmer v. Johnson & Johnson Consumer Inc. | 07/22/2026 | 1:26-cv-06201 |
| Nieves v. Johnson & Johnson Consumer, Inc. | 07/01/2026 | 1:26-cv-05579 |
| McCrary v. Johnson & Johnson Consumer Inc. | 06/29/2026 | 1:26-cv-05516 |
| Ingraham v. Johnson & Johnson Consumer Inc. | 06/25/2026 | 1:26-cv-05380 |
| Ludwick-Rutterbush v. Johnson & Johnson Consumer Inc. | 06/23/2026 | 1:26-cv-05280 |
| Brooks v. Johnson & Johnson Consumer Inc. | 06/22/2026 | 1:26-cv-05227 |
| Rosenfeld v. Johnson & Johnson Consumer Inc. | 06/11/2026 | 1:26-cv-04957 |
| Sharp v. Johnson & Johnson Consumer, Inc. | 05/29/2026 | 1:26-cv-04532 |
| Abney v. Johnson & Johnson Consumer, Inc. | 05/28/2026 | 1:26-cv-04479 |
| Lawless v. Johnson & Johnson Consumer Inc. | 05/27/2026 | 1:26-cv-04398 |
| Baukovic v. Johnson & Johnson Consumer Inc. | 05/18/2026 | 1:26-cv-04148 |
| Plump v. Johnson & Johnson Consumer Inc. | 05/14/2026 | 1:26-cv-04037 |
| Bowen v. Johnson & Johnson Consumer, Inc. | 04/28/2026 | 1:26-cv-03512 |
| Schomer v. Johnson & Johnson Consumer Inc. | 04/17/2026 | 1:26-cv-03183 |
| Lucas v. Johnson & Johnson Consumer Inc. | 03/26/2026 | 1:26-cv-02484 |
| Aoun v. Johnson & Johnson Consumer Inc. | 03/24/2026 | 1:26-cv-02397 |
| Davis v. Johnson & Johnson Consumer, Inc. | 03/13/2026 | 1:26-cv-02092 |
| Young v. Johnson & Johnson Consumer Inc. | 02/27/2026 | 1:26-cv-01659 |
| Goode v. Johnson & Johnson Consumer, Inc. | 02/27/2026 | 1:26-cv-01630 |
| Calicchia v. Johnson & Johnson Consumer Inc. | 02/23/2026 | 1:26-cv-01495 |
| Johnson v. Johnson & Johnson Consumer Inc. | 02/19/2026 | 1:26-cv-01408 |
| Jones v. Johnson & Johnson Consumer Inc. | 02/19/2026 | 1:26-cv-01406 |
| Russell v. Johnson & Johnson Consumer Inc. | 02/04/2026 | 1:26-cv-00969 |
| Barwick v. Johnson & Johnson Consumer, Inc. | 01/30/2026 | 1:26-cv-00815 |
| Spadafora v. Johnson & Johnson Consumer Inc. | 01/27/2026 | 1:26-cv-00701 |
| Hanus v. Johnson & Johnson Consumer, Inc. | 01/22/2026 | 1:26-cv-00600 |
Method and limits. Compiled by Marin & Murphy Law Firm from the Free Law Project’s RECAP archive of PACER dockets (CourtListener): Southern District of New York dockets whose text references acetaminophen, filed since January 1, 2026, captioned against Johnson & Johnson Consumer (five unrelated dockets matching the term were excluded). RECAP indexes only the dockets its users have retrieved, so the table is a sample of the MDL 3043 docket, not the whole of it. Captions are reproduced as docketed; entries without a description are counted, not characterized. Refreshed weekly.
What This Means for New Claimants
If you are a parent following this news, here is the practical takeaway. Cases that had ended are back before the trial court, and new claims can still be reviewed. You do not need to have been part of the appeal to ask about filing.
Filing deadlines, called statutes of limitations, are set by state law and vary by state. Many states pause a child’s deadline while the child is a minor, though not for every claim. A lawyer licensed in your state can tell you which deadline applies; the free review doesn’t calculate or track it.
To see how the free review works and the firm’s current screening criteria, read how to sign up for the Tylenol autism lawsuit, or start with the Tylenol autism and ADHD lawsuit hub.
Frequently Asked Questions
What did the July 13, 2026 appeals court ruling actually decide?
The U.S. Court of Appeals for the Second Circuit vacated the trial court’s judgments for the defendants and sent the cases back. It held that the trial court exceeded its discretion in excluding three of the plaintiffs’ general-causation experts and held that the defendants had not shown that federal law blocks the failure-to-warn claims. On October 16, 2026, it denied rehearing in the main appeal, and on October 28, 2026, its mandate was docketed in the trial court. The court did not decide whether Tylenol causes autism or ADHD.
Does this mean Tylenol causes autism or ADHD?
No. The court expressly did not decide that question. Some studies have reported associations between acetaminophen use in pregnancy and autism or ADHD, but no court has found that acetaminophen causes either condition. The appeals court decided legal questions about the experts and federal preemption, not whether acetaminophen causes either condition.
How many Tylenol lawsuits were revived?
The appeals court set aside the rulings that had ended the federal cases; its opinion says the trial court had granted summary judgment in about 550 cases. The cases returned to the federal MDL in the Southern District of New York on October 28, 2026, when the Second Circuit’s mandate was docketed there.
Which experts did the appeals court rule on?
The court held that the trial court should not have excluded Dr. Andrea Baccarelli, an epidemiologist; Dr. Eric Hollander, a psychiatrist; and Dr. Brandon Pearson, a toxicologist. In Phippen it sent Dr. Roberta Ness’s exclusion back for reconsideration. Judge Cote will set the next steps.
In July 2026 the Second Circuit (Nos. 24-916(L) et al.) held that the testimony of three of the plaintiffs’ experts, Baccarelli, Hollander and Pearson, is admissible on the record before the trial court, which means a jury may hear it and decide what weight to give it. It also held that the trial court erred in granting summary judgment on the ground that the plaintiffs lacked any evidence of general causation. The cases in the main appeal are back before the trial court, and further motions, including on summary judgment, remain possible. No case has gone to trial and no settlement exists.
Did the court rule that federal law blocks the Tylenol claims?
No. The court held that the failure-to-warn claims are not preempted. It explained that the FDA’s pregnancy warning regulation requires a general warning but does not forbid a manufacturer from adding a supplemental warning about a specific risk.
Is there a Tylenol autism settlement yet?
No. As of November 7, 2026, we have found no settlement, and no liability has been established. On October 16, 2026, the Second Circuit denied rehearing in the main appeal, so its July 13, 2026 decision stands. No one can say whether there will be a settlement, or when.
What happens next in the litigation?
The Second Circuit’s mandate, returning the cases to the trial court, was docketed there on October 28, 2026. As of November 7, 2026, no petition for review has been filed in the main appeal. Any petition is due January 14, 2027, and that deadline can be extended. The October 16, 2026 order denying rehearing also lists the Phippen appeal. No one can say how long the cases will take or how they will end.
Can I still file a Tylenol autism or ADHD claim?
Possibly. New claims can still be reviewed, and the firm’s free review checks whether your family fits its current screening criteria. Filing deadlines are set by state law and vary by state; a lawyer licensed in your state can tell you which deadline applies, and the free review doesn’t calculate or track it.
Free, confidential case review. No fee unless there is a recovery; costs are advanced and reimbursed only out of a recovery. Start your free case review or call (888) 348-2735.
Attorney advertising. This page is for general information only and is not legal or medical advice. Reading it or contacting Marin & Murphy Law Firm does not create an attorney-client relationship. No settlement has been reached in the Tylenol (acetaminophen) autism/ADHD litigation, no liability has been established, and no outcome is guaranteed. Prior results do not guarantee a similar outcome. Courts and regulators, including the FDA, have not concluded that acetaminophen causes autism or ADHD; the science remains subject to ongoing debate. There is no fee unless there is a recovery; costs are advanced and reimbursed only out of a recovery.
Go deeper on the ruling: What the July 2026 appeals ruling actually decided (experts and preemption), and if this affected your family, what changed for previously denied families.
Read next
Tylenol (acetaminophen) autism and ADHD claims are handled together with co-counsel, who carry principal responsibility for these matters; Marin & Murphy Law Firm maintains joint responsibility. Whether a claim is accepted is determined after review, and no attorney-client relationship is created until a written engagement agreement is signed.